Tryton Announces 6-Month Results for Side Branch Stent System at TCT

September 29, 2010—Tryton Medical, Inc., (Durham, NC) announced that David P. Foley, MD, presented interim 6-month results from the E-Tryton registry, which is studying the company's side branch stent system, at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, DC.

According to the company, results from 253 patients in the E-Tryton registry demonstrated low rates of target lesion revascularization (TLR) and side branch failure (3.6% and 1.2%, respectively), with no incidences of stent thromboses.

Also at TCT, Antonio L. Bartorelli, MD, presented 9-month angiographic and intravenous ultrasound follow-up results from the IUVANT study of the device, which demonstrated a 3.2% rate of TLR, and no stent thromboses.

Prof. Bartorelli concluded, “These preliminary data suggest that the Tryton stent provides a reliable and reproducible strategy to stent the side branch and its origin, showing complete scaffolding and coverage of the side branch ostium and very modest in-stent neointimal growth at follow-up.”

The company stated that the Tryton side branch stent system offers a dedicated strategy for treating atherosclerotic lesions in the side branch at the site of a bifurcation. The device's cobalt chromium stent is deployed in the side branch artery using a standard single-wire, balloon-expandable stent delivery system, and then a conventional drug-eluting stent is placed in the main vessel. The stent system has received CE Mark approval. It is not approved in the United States.